{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:07:55Z","timestamp":1788782875251,"version":"build-2803163510"},"reference-count":66,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["22 2144 Pj"],"award-info":[{"award-number":["22 2144 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["23 0650 JIA"],"award-info":[{"award-number":["23 0650 JIA"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["23 2747 Pj"],"award-info":[{"award-number":["23 2747 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["24 3523 Pj"],"award-info":[{"award-number":["24 3523 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["25 4586 Pj"],"award-info":[{"award-number":["25 4586 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021-04289"],"award-info":[{"award-number":["2021-04289"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2022-01519"],"award-info":[{"award-number":["2022-01519"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2023-02158"],"award-info":[{"award-number":["2023-02158"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Folate receptor alpha (FR\u03b1) is frequently overexpressed in ovarian cancer while showing limited expression in healthy tissues. Targeting of FR\u03b1 has been extensively investigated using antibody-based therapies but less so with small scaffold proteins. Small scaffold proteins represent an alternative approach with potential advantages such as site-specific conjugation and deep tumor penetration but are limited by a short half-life. Here, we describe the development of a dual-surfaced ADAPT scaffold protein (6 kDa) with simultaneous bispecificity for FR\u03b1 and albumin. Using combinatorial libraries and phage display, we identified a candidate, termed ADAPT22, with high isoform selectivity and subnanomolar affinity for FR\u03b1 (KD = 0.8 nM), paired with a low nanomolar affinity for albumin (KD = 2.4 nM). Importantly, ADAPT22 is able to interact with both targets simultaneously, truly combining extended retention in blood via albumin association and tumor targeting via FR\u03b1 within a single-domain protein. The simultaneous nature was verified in vitro to soluble proteins and to FR\u03b1-positive cells and in vivo using a mouse xenograft model. In mice, ADAPT22 demonstrated markedly extended blood retention, reduced renal uptake, and specific accumulation in FR\u03b1-positive tumors, confirming simultaneous dual-surface binding. To the best of our knowledge, this is the smallest half-life extended affinity protein designed for therapeutic targeting of FR\u03b1.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00683","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:14:31Z","timestamp":1785849271000},"page":"4743-4757","source":"Crossref","is-referenced-by-count":0,"title":["Integrating\nTumor Targeting and Half-Life Extension\ninto a Dual-Surfaced Single-Domain ADAPT Protein"],"prefix":"10.1021","volume":"23","author":[{"given":"Emma","family":"Larsson","sequence":"first","affiliation":[{"name":"KTH Royal Institute of Technology , , ,","place":["Stockholm, Sweden, 106 91"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeen","family":"Ud-din","sequence":"additional","affiliation":[{"name":"Uppsala University , , ,","place":["Uppsala, Sweden, 751 85"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Bitzios","sequence":"additional","affiliation":[{"name":"Uppsala University , , ,","place":["Uppsala, Sweden, 751 85"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Recasens Pe\u0301rez-Vera","sequence":"additional","affiliation":[{"name":"Uppsala University , , ,","place":["Uppsala, Sweden, 751 85"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7067-9173","authenticated-orcid":true,"given":"Hanna","family":"Tegel","sequence":"additional","affiliation":[{"name":"KTH Royal Institute of Technology , , ,","place":["Stockholm, Sweden, 106 91"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6120-2683","authenticated-orcid":true,"given":"Anna","family":"Orlova","sequence":"additional","affiliation":[{"name":"Uppsala University , , ,","place":["Uppsala, Sweden, 751 23"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-1734","authenticated-orcid":true,"given":"Vladimir","family":"Tolmachev","sequence":"additional","affiliation":[{"name":"Uppsala University , , ,","place":["Uppsala, Sweden, 751 85"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-3909","authenticated-orcid":true,"given":"Anzhelika","family":"Vorobyeva","sequence":"additional","affiliation":[{"name":"Uppsala University , , ,","place":["Uppsala, Sweden, 751 85"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0605-8417","authenticated-orcid":true,"given":"Sophia","family":"Hober","sequence":"additional","affiliation":[{"name":"KTH Royal Institute of Technology , , ,","place":["Stockholm, Sweden, 106 91"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2026090707075619400_cit1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"Jama"},{"key":"2026090707075619400_cit2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41416-022-02031-x","article-title":"Folate receptor alpha\nin ovarian cancer tissue and patient serum is associated with disease\nburden and treatment outcomes","volume":"128","author":"Bax","year":"2023","journal-title":"Br. J. Cancer"},{"key":"2026090707075619400_cit3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha\nas a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol Oncol"},{"key":"2026090707075619400_cit4","first-page":"3567","article-title":"Alpha-folate\nreceptor\nexpression in epithelial ovarian carcinoma and non-neoplastic ovarian\ntissue","volume":"28","author":"Markert","year":"2008","journal-title":"Anticancer Res."},{"key":"2026090707075619400_cit5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate\nreceptor expression\nin carcinomas and normal tissues determined by a quantitative radioligand\nbinding assay","volume":"338","author":"Parker","year":"2005","journal-title":"Anal. Biochem."},{"key":"2026090707075619400_cit6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/PAI.0000000000000476","article-title":"Folate receptor alpha\nexpression in platinum resistant\/refractory ovarian carcinomas and\nprimary endocervical adenocarcinomas","volume":"26","author":"Rubinsak","year":"2018","journal-title":"Appl.\nImmunohistochem Mol. Morphol"},{"key":"2026090707075619400_cit7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2013.03.024","article-title":"Folate\nreceptor alpha\n(FRA) expression remains unchanged in epithelial ovarian and endometrial\ncancer after chemotherapy","volume":"130","author":"Despierre","year":"2013","journal-title":"Gynecol Oncol"},{"key":"2026090707075619400_cit8","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1080\/14796694.2025.2513848","article-title":"Mirvetuximab soravtansine\nfor the treatment of epithelial ovarian, fallopian tube, or primary\nperitoneal cancer","volume":"21","author":"Silverstein","year":"2025","journal-title":"Future Oncol"},{"key":"2026090707075619400_cit9","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine\nin FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J. Med."},{"key":"2026090707075619400_cit10","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1158\/1078-0432.CCR-25-1749","article-title":"Derivation of AZD5335,\na novel FR\u03b1-targeted TOP1i-loaded ADC, for the treatment of\nFR\u03b1-expressing cancers","volume":"31","author":"Zoeller","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"2026090707075619400_cit11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1186\/s12951-024-03008-z","article-title":"Development and evaluation\nof a single domain antibody targeting folate receptor alpha for radioligand\ntherapy","volume":"22","author":"Dewulf","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"2026090707075619400_cit12","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s00259-020-04980-y","article-title":"Preclinical\nevaluation of 5-methyltetrahydrofolate-based radioconjugates-new perspectives\nfor folate receptor-targeted radionuclide therapy","volume":"48","author":"Guzik","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026090707075619400_cit13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/cancers16020333","article-title":"Preclinical evaluation\nof novel folate receptor 1-directed CAR T cells for ovarian cancer","volume":"16","author":"Daigre","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026090707075619400_cit14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1039\/D2CB00094F","article-title":"Protein scaffolds: antibody alternatives for cancer\ndiagnosis and therapy","volume":"3","author":"Luo","year":"2022","journal-title":"RSC Chem. Biol."},{"key":"2026090707075619400_cit15","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1038\/emm.2017.35","article-title":"Affibody molecules\nas engineered protein drugs","volume":"49","author":"Frejd","year":"2017","journal-title":"Experimental &\nMolecular Medicine"},{"key":"2026090707075619400_cit16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40259-020-00429-8","article-title":"Beyond\nantibodies: the DARPin\u00ae\ndrug platform","volume":"34","author":"Stumpp","year":"2020","journal-title":"BioDrugs"},{"key":"2026090707075619400_cit17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib7020016","article-title":"Small-format drug conjugates:\na viable alternative to ADCs for solid tumours?","volume":"7","author":"Deonarain","year":"2018","journal-title":"Antibodies (Basel)"},{"key":"2026090707075619400_cit18","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1158\/0008-5472.CAN-14-3497","article-title":"ADAPT, a novel scaffold\nprotein-based probe for radionuclide imaging of molecular targets\nthat are expressed in disseminated cancers","volume":"75","author":"Garousi","year":"2015","journal-title":"Cancer Res."},{"key":"2026090707075619400_cit19","doi-asserted-by":"publisher","first-page":"23s","DOI":"10.2967\/jnumed.121.262751","article-title":"Normal-tissue tolerance\nto radiopharmaceutical therapies, the knowns and the unknowns","volume":"62","author":"Wahl","year":"2021","journal-title":"J. Nucl. Med."},{"key":"2026090707075619400_cit20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fimmu.2014.00682","article-title":"Unraveling\nthe interaction\nbetween FcRn and albumin: opportunities for design of albumin-based\ntherapeutics","volume":"5","author":"Sand","year":"2015","journal-title":"Front. Immunol."},{"key":"2026090707075619400_cit21","doi-asserted-by":"publisher","first-page":"8114","DOI":"10.1074\/jbc.M109943200","article-title":"Structure, specificity,\nand mode of interaction for bacterial albumin-binding modules","volume":"277","author":"Johansson","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2026090707075619400_cit22","doi-asserted-by":"publisher","first-page":"42924","DOI":"10.1074\/jbc.M406957200","article-title":"Crystal structure and\nbiological implications of a bacterial albumin binding module in complex\nwith human serum albumin","volume":"279","author":"Lejon","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2026090707075619400_cit23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1110\/ps.02802","article-title":"Mutational analysis\nof the interaction between albumin-binding domain from streptococcal\nprotein G and human serum albumin","volume":"11","author":"Linhult","year":"2002","journal-title":"Protein Sci."},{"key":"2026090707075619400_cit24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2967\/jnumed.112.110700","article-title":"Site-specific radiometal\nlabeling and improved biodistribution using ABY-027, a novel HER2-targeting\naffibody molecule-albumin-binding domain fusion protein","volume":"54","author":"Orlova","year":"2013","journal-title":"J. Nucl. Med."},{"key":"2026090707075619400_cit25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jconrel.2024.04.051","article-title":"Half-life\nextension\nvia ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate\ncompared to PAS- and XTENylation","volume":"370","author":"Zhang","year":"2024","journal-title":"J. Controlled\nRelease"},{"key":"2026090707075619400_cit26","doi-asserted-by":"publisher","first-page":"120381","DOI":"10.1016\/j.biomaterials.2020.120381","article-title":"Radionuclide therapy\nusing ABD-fused ADAPT scaffold protein: proof of principle","volume":"266","author":"Garousi","year":"2021","journal-title":"Biomaterials"},{"key":"2026090707075619400_cit27","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.3390\/ijms26115236","article-title":"Targeting of epithelial\ncell adhesion molecule-expressing malignant tumors using an albumin-binding\ndomain-fused designed ankyrin repeat protein: effect of the molecular\narchitecture","volume":"26","author":"Tolmachev","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"2026090707075619400_cit28","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.3390\/ijms25084246","article-title":"Preclinical evaluation\nof HER2-targeting DARPin G3: impact of albumin-binding domain (ABD)\nfusion","volume":"25","author":"Deyev","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"2026090707075619400_cit29","doi-asserted-by":"publisher","first-page":"1893888","DOI":"10.1080\/19420862.2021.1893888","article-title":"Extended plasma half-life\nof albumin-binding domain fused human IgA upon pH-dependent albumin\nengagement of human FcRn in vitro and in vivo","volume":"13","author":"Mester","year":"2021","journal-title":"mAbs"},{"key":"2026090707075619400_cit30","doi-asserted-by":"publisher","first-page":"e103094","DOI":"10.1371\/journal.pone.0103094","article-title":"Engineering of bispecific\naffinity proteins with high affinity for ERBB2 and adaptable binding\nto albumin","volume":"9","author":"Nilvebrant","year":"2014","journal-title":"PLoS One"},{"key":"2026090707075619400_cit31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2967\/jnumed.120.248799","article-title":"Phase\nI study of (99m)Tc-ADAPT6,\na scaffold protein-based probe for visualization of HER2 expression\nin breast cancer","volume":"62","author":"Bragina","year":"2021","journal-title":"J. Nucl. Med."},{"key":"2026090707075619400_cit32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1021\/acs.molpharmaceut.0c00975","article-title":"Small bispecific affinity proteins for simultaneous target binding\nand albumin-associated half-life extension","volume":"18","author":"von Witting","year":"2021","journal-title":"Mol. Pharmaceutics"},{"key":"2026090707075619400_cit33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0168-1656(00)00259-5","article-title":"Stability towards alkaline\nconditions can be engineered into a protein ligand","volume":"80","author":"Gu\u0308lich","year":"2000","journal-title":"J. Biotechnol."},{"key":"2026090707075619400_cit34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.nbt.2020.05.002","article-title":"High throughput\ngeneration\nof a resource of the human secretome in mammalian cells","volume":"58","author":"Tegel","year":"2020","journal-title":"N Biotechnol"},{"key":"2026090707075619400_cit35","doi-asserted-by":"publisher","first-page":"gzad011","DOI":"10.1093\/protein\/gzad011","article-title":"An easy-to-use high-throughput\nselection system for the discovery of recombinant protein binders\nfrom alternative scaffold libraries","volume":"36","author":"Mo\u0308ller","year":"2023","journal-title":"Protein\nEng. Des. Sel."},{"issue":"Suppl. 1","key":"2026090707075619400_cit36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/elps.200900140","article-title":"Automated comparative protein structure\nmodeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective","volume":"30","author":"Guex","year":"2009","journal-title":"Electrophoresis"},{"key":"2026090707075619400_cit37","doi-asserted-by":"publisher","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology\nmodelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2026090707075619400_cit38","doi-asserted-by":"publisher","first-page":"7605","DOI":"10.1021\/bi00081a001","article-title":"Helix stop signals in proteins and peptides: the capping\nbox","volume":"32","author":"Harper","year":"1993","journal-title":"Biochemistry"},{"key":"2026090707075619400_cit39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/protein\/10.5.487","article-title":"A consensus residue\nanalysis of loop and helix-capping\nresidues in four-alpha-helical-bundle proteins","volume":"10","author":"Parker","year":"1997","journal-title":"Protein Eng."},{"key":"2026090707075619400_cit40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1126\/science.aan0693","article-title":"Global analysis of protein\nfolding using massively parallel design, synthesis, and testing","volume":"357","author":"Rocklin","year":"2017","journal-title":"Science"},{"key":"2026090707075619400_cit41","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/12890","article-title":"Stable one-step technetium-99m\nlabeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl\ncomplex","volume":"17","author":"Waibel","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"2026090707075619400_cit42","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jconrel.2023.02.005","article-title":"Comparison of HER2-targeted affibody conjugates\nloaded with auristatin- and maytansine-derived drugs","volume":"355","author":"Yin","year":"2023","journal-title":"J. Controlled Release"},{"key":"2026090707075619400_cit43","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1089\/cbr.2008.0464","article-title":"Slow internalization of anti-HER2\nsynthetic affibody\nmonomer 111In-DOTA-ZHER2:342-pep2: implications for development of\nlabeled tracers","volume":"23","author":"W\u00e5llberg","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"2026090707075619400_cit44","doi-asserted-by":"publisher","first-page":"15180","DOI":"10.1073\/pnas.1308827110","article-title":"Structures of human\nfolate receptors reveal biological trafficking states and diversity\nin folate and antifolate recognition","volume":"110","author":"Wibowo","year":"2013","journal-title":"Proc.\nNatl. Acad. Sci. U. S. A."},{"key":"2026090707075619400_cit45","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/protein\/gzn028","article-title":"Engineering of a femtomolar\naffinity binding protein to human serum albumin","volume":"21","author":"Jonsson","year":"2008","journal-title":"Protein Eng. Des Sel"},{"key":"2026090707075619400_cit46","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/0014-5793(95)01452-7","article-title":"The serum albumin-binding\ndomain of streptococcal protein G is a three-helical bundle: a heteronuclear\nNMR study","volume":"378","author":"Kraulis","year":"1996","journal-title":"FEBS Lett."},{"key":"2026090707075619400_cit47","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1126\/science.3381086","article-title":"Amino acid\npreferences for specific locations at the\nends of alpha helices","volume":"240","author":"Richardson","year":"1988","journal-title":"Science"},{"key":"2026090707075619400_cit48","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-\u03b1\n(FR\u03b1)-targeting antibody-drug conjugate, exhibits potent targeted\nantitumor activity against FR\u03b1-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol. Cancer Ther"},{"key":"2026090707075619400_cit49","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.2967\/jnumed.120.255760","article-title":"Identification\nof a\nPET radiotracer for imaging of the folate receptor-\u03b1: a potential\ntool to select patients for targeted tumor therapy","volume":"62","author":"Guzik","year":"2021","journal-title":"J. Nucl. Med."},{"key":"2026090707075619400_cit50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/(SICI)1097-0215(19980105)75:1&lt;125::AID-IJC19&gt;3.0.CO;2-F","article-title":"Role of\nfolate receptor\nand reduced folate carrier in the transport of 5-methyltetrahydrofolic\nacid in human ovarian carcinoma cells","volume":"75","author":"Corona","year":"1998","journal-title":"Int.\nJ. Cancer"},{"key":"2026090707075619400_cit51","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1021\/acs.bioconjchem.6b00465","article-title":"Influence of the N-terminal\ncomposition on targeting properties of radiometal-labeled anti-HER2\nscaffold protein ADAPT6","volume":"27","author":"Garousi","year":"2016","journal-title":"Bioconjug Chem."},{"key":"2026090707075619400_cit52","doi-asserted-by":"publisher","first-page":"2470309","DOI":"10.1080\/19420862.2025.2470309","article-title":"Folate receptor alpha\nfor cancer therapy: an antibody and antibody-drug conjugate target\ncoming of age","volume":"17","author":"Liu","year":"2025","journal-title":"mAbs"},{"key":"2026090707075619400_cit53","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/19420862.2015.1008345","article-title":"Albumin-deficient mouse\nmodels for studying metabolism of human albumin and pharmacokinetics\nof albumin-based drugs","volume":"7","author":"Roopenian","year":"2015","journal-title":"MAbs"},{"key":"2026090707075619400_cit54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/cancers13010085","article-title":"Drug conjugates based\non a monovalent affibody targeting vector can efficiently eradicate\nHER2 positive human yumors in an experimental mouse model","volume":"13","author":"Xu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026090707075619400_cit55","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1023\/A:1005713115147","article-title":"Folate receptors as\npotential therapeutic targets in choroid plexus tumors of SV40 transgenic\nmice","volume":"32","author":"Patrick","year":"1997","journal-title":"J. Neurooncol."},{"key":"2026090707075619400_cit56","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12987-022-00391-3","article-title":"Novel localization\nof folate transport systems in the murine central nervous system","volume":"19","author":"Sangha","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"2026090707075619400_cit57","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2967\/jnumed.107.045856","article-title":"SPECT study of folate\nreceptor-positive malignant and normal tissues in mice using a novel\n99mTc-radiofolate","volume":"49","author":"Mu\u0308ller","year":"2008","journal-title":"J. Nucl. Med."},{"key":"2026090707075619400_cit58","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.3390\/nu11102353","article-title":"Renal reabsorption of\nfolates: pharmacological and toxicological snapshots","volume":"11","author":"Samodelov","year":"2019","journal-title":"Nutrients"},{"key":"2026090707075619400_cit59","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.3390\/molecules25194448","article-title":"Investigation of a pharmacological\napproach for reduction of renal uptake of radiolabeled ADAPT scaffold\nprotein","volume":"25","author":"Vorobyeva","year":"2020","journal-title":"Molecules"},{"key":"2026090707075619400_cit60","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ard.2025.02.019","article-title":"Efficacy\nand safety\nof izokibep in patients with active psoriatic arthritis: a randomised,\ndouble-blind, placebo-controlled, phase 2 study","volume":"84","author":"Taylor","year":"2025","journal-title":"Ann. Rheum Dis"},{"key":"2026090707075619400_cit61","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejpb.2018.11.004","article-title":"Comparative\nevaluation\nof dimeric and monomeric forms of ADAPT scaffold protein for targeting\nof HER2-expressing tumours","volume":"134","author":"Garousi","year":"2019","journal-title":"Eur. J. Pharm. Biopharm"},{"key":"2026090707075619400_cit62","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2019.11.014","article-title":"Size and affinity kinetics\nof nanobodies influence targeting and penetration of solid tumours","volume":"317","author":"Debie","year":"2020","journal-title":"J. Controlled Release"},{"key":"2026090707075619400_cit63","doi-asserted-by":"publisher","first-page":"15181","DOI":"10.3390\/ijms232315181","article-title":"Direct\nin vivo comparison\nof (99m)Tc-labeled scaffold proteins, DARPin G3 and ADAPT6, for visualization\nof HER2 expression and monitoring of early response for trastuzumab\ntherapy","volume":"23","author":"Tolmachev","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"2026090707075619400_cit64","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1158\/1535-7163.MCT-09-0195","article-title":"A modeling analysis of the effects of molecular size\nand binding affinity on tumor targeting","volume":"8","author":"Schmidt","year":"2009","journal-title":"Mol.\nCancer Ther"},{"key":"2026090707075619400_cit65","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.neo.2023.100962","article-title":"Impact of tissue penetration\nand albumin binding on design of T cell targeted bispecific agents","volume":"48","author":"Kopp","year":"2024","journal-title":"Neoplasia"},{"key":"2026090707075619400_cit66","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/0008-5472.CAN-06-2531","article-title":"Imaging tumors with an albumin-binding Fab,\na novel tumor-targeting agent","volume":"67","author":"Dennis","year":"2007","journal-title":"Cancer Res."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00683","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4743\/66320521\/acs.molpharmaceut.6c00683.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4743\/66320521\/acs.molpharmaceut.6c00683.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:15:41Z","timestamp":1788779741000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/9\/4743\/5236189\/Integrating-Tumor-Targeting-and-Half-Life"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,9,7]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00683","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}